Finance
Net loss reported: $0.36 per share
Published in Gene Therapy Weekly, September 19th, 2002
At June 30, 2002, Avigen had $133 million in current assets, primarily cash equivalents and short-term investments, down $8 million from $141 million at March 31, 2002, the end of the previous quarter.
"Avigen continues to make progress towards the commercialization of an AAV vector based gene therapy," said John Monahan, PhD, president, and CEO. "During the last quarter we reported developments on many fronts including research advances, manufacturing improvements and the strengthening of our intellectual property...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2002-09-19)
More Articles from Gene Therapy Weekly
- Hypercholesterolemia
Repetitive therapy a possibility for treating hereditary cholesterol disease - Prostate Cancer
Novel gene product facilitates suicide gene tracking in male cancers - Cancer Therapy
Gene for common cold makes cancer cells susceptible to therapeutic attack - Diabetes Mellitus
Minigene transfer ignites insulin production in response to glucose - Virology
HIV targets active genes in cells - Appointments
Robert C. Moellering, Jr., named to Ricerca's scientific advisory board - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
